Hariharasudan Mani, MD
Hematology & Oncology · Pottsville, PANPI 1922245489
Payments from drug & device makers
What this record shows
This record is dominated by education: $954 of the $1,371 with a category attached, or 69.6%. It is spread thinly across 16 manufacturers, the largest accounting for just 21.7%. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 28 payments — averaging $48.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$298
- Incyte Corporation$285
- Gilead$208
- AVEO Pharmaceuticals, Inc.$100
- AstraZeneca$99
- Pfizer$86
- plus $295 from 10 others
What the payments were for
- Food & beverage$41730%
- Education$95470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $298 |
| Incyte Corporation | 3 | $285 |
| Gilead | 2 | $208 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| AstraZeneca | 1 | $99 |
| Pfizer | 7 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Bayer | 2 | $42 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| AbbVie | 1 | $22 |
| Sobi, Inc | 1 | $20 |
| Merck | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
How this compares
$1,371 in reported general payments places this provider in the 50th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 14 | $155 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Pottsville
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.